June 15th 2022
Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.
June 2nd 2022
The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.
June 1st 2022
The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
May 28th 2022
RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.
May 26th 2022
The chief executive officer of Ring Therapeutics, Tuyen Ong, MD, discussed the potential of anellovirus vectors for use in gene therapy.
The vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.
May 25th 2022
The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.
All study participants met criteria to remain off enzyme replacement therapy through 104 weeks after treatment.
May 24th 2022
The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.
May 23rd 2022
The cell therapy was tolerated although there was a SUSAR of GGT elevations.